Hepatitis C antibody - MRC Technology/NewSummit Biopharma

Drug Profile

Hepatitis C antibody - MRC Technology/NewSummit Biopharma

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MRC Technology; University of Glasgow
  • Developer LifeArc
  • Class Antibodies; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis C

Most Recent Events

  • 15 Jun 2017 MRC Technology is now called LifeArc
  • 14 Mar 2017 Hepatitis C antibody licensed to NewSummit Biopharma
  • 14 Mar 2017 Early research in Hepatitis C in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top